| Literature DB >> 32178323 |
Yaqing Wu1,2,3, Hongying Jiang1,2, Jyuan-Siou Lin3, Jia Liu1,2, Chang-Jer Wu3,4,5,6, Ruian Xu1,2,7.
Abstract
The aims of this study were to investigate the antioxidant, hypolipidemic and hepatic protective effects of Phascolosoma esculenta polysaccharides (PEP). PEP was prepared from Phascolosoma esculenta by enzyme hydrolysis and its characterization was analyzed. The antioxidant activities of PEP were evaluated by the assays of scavenging 1,1-Diphenyl-2-picrylhydrazyl (DPPH), superoxide anion, hydroxyl radicals and chelating ferrous ion in vitro. It showed that PEP could scavenge radicals effectively and had favorable antioxidant activities. In the meantime, the hypolipidemic effect of PEP was investigated in vivo by using mice model fed with high-fat diet with or without PEP treatment. Compared with the hyperlipidemic mice without treatment, the serum levels of total cholesterol (TC) (30.1-35.7%, p < 0.01), triglyceride (TG) (24.5-50.8%, p < 0.01 or p < 0.05), low-density lipoprotein cholesterol (LDL-C) (49.6-56.8%, p < 0.01) and liver levels of TC (21.0-28.4%, p < 0.01), TG (23.8-37.0%, p < 0.01) decreased significantly, whereas serum high-density lipoprotein cholesterol (HDL-C) (47.7-59.9%, p < 0.01 or p < 0.05) increased significantly after treatment with different dosage of PEP (0.2, 0.4 and 0.8 g per kg body weight, respectively). In addition, superoxide dismutase (SOD) (10.2-22.2% and 18.8-26.9%, p < 0.05), glutathione peroxidase (GSH-Px) (11.9-15.4% and 26.6-30.4%, p < 0.05) activities in serum and liver enhanced markedly while aspartate aminotransferase (AST) (18.7-29.6% and 42.4-58.0%, p < 0.05), alanine transaminase (ALT) (42.7-46.0% and 31.2-42.2%, p < 0.05) activities, as well as the levels of malondialdehyde (MDA) (15.9-24.4% and 15.0-16.8%, p < 0.01 or p < 0.05) in serum and liver reduced markedly. Moreover, the histopathological observation of livers indicated that PEP could attenuate liver cell injury. The animal experimental results demonstrated that PEP exerted hypolipidemic and hepatoprotective roles in hyperlipidemic mice. In summary, our results above suggest that PEP might be a potential natural antioxidant and utilized as a therapeutic candidate for hyperlipidemia.Entities:
Keywords: Phascolosoma esculenta; antioxidant activity; hepatic protective effects; hypolipidemic effect; polysaccharide
Mesh:
Substances:
Year: 2020 PMID: 32178323 PMCID: PMC7142949 DOI: 10.3390/md18030158
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The monosaccharide composition of P. esculenta polysaccharide (PEP) detected by pre-column derivatization high performance liquid chromatography (HPLC). The number indicated the corresponding monosaccharide. 1, mannose; 2, ribose; 3, rhamnose; 4, glucuronic acid; 5, galacturonic acid; 6, glucose; 7, galactose; 8, xylose; 9, arabinose; 10, fucose.
Figure 2Antioxidant activities in vitro of PEP. (a) DPPH free radical scavenging activity; (b) Ferrous ion chelating activity; (c) Superoxide anion radical scavenging activity; (d) Hydroxyl radical scavenging activity. L-ascorbic acid and EDTA used as positive control. Data are expressed as a mean ± standard deviation (n = 3). ** p < 0.01: compared with the positive control at the same concentration.
Figure 3Changes in body weight of the mice after fed with different foods for 75 days. The normal (N) group was fed the basic diet; the negative control (NC) group was fed with a high-fat diet with 78.8% basal feed, 1% cholesterol, 10% egg yolk power, 10% lard, 0.2% bile salts; the positive control (PC) group was fed with a high-fat diet feed plus Soybean lecithin soft capsule 0.6 g·kg−1 body weight; the PE group was fed with a high-fat diet feed plus PE powder 1.35 g·kg−1 body weight; the low-dose PEP (PEP-L) group was fed a high-fat diet feed plus PEP 0.2 g·kg−1 body weight; the middle-dose PEP (PEP-M) group was fed with a high-fat diet feed plus PEP 0.4 g·kg−1 body weight; the high-dose PEP (PEP-H) group was fed with a high-fat diet feed plus PEP 0.8 g·kg−1 body weight.
Effects of PEP on serum lipid levels (n = 10, mean ± standard deviation).
| Group | TG (mmol·L−1) | TC (mmol·L−1) | LDL-C (mmol·L−1) | HDL-C (mmol·L−1) | AI |
|---|---|---|---|---|---|
| N | 1.19 ± 0.27 | 4.02 ± 0.66 | 0.27 ± 0.11 | 2.15 ± 0.68 | 1.09 ± 0.91 |
| NC | 2.52 ± 0.66 ## | 7.79 ± 1.70 ## | 1.08 ± 0.45 ## | 0.89 ± 0.23 ## | 8.40 ± 3.15 ## |
| PC | 1.56 ± 0.57 ** | 5.35 ± 0.99 ** | 0.47 ± 0.24 ** | 1.47 ± 0.38 ** | 2.86 ± 1.21 ** |
| PE | 1.53 ± 0.32 ** | 5.40 ± 0.74 ** | 0.45 ± 0.35 ** | 1.38 ± 0.54 * | 3.25 ± 1.14 ** |
| PEP-L | 1.90 ± 0.55 * | 5.45 ± 1.41 ** | 0.47 ± 0.41 ** | 1.31 ± 0.39 * | 3.36 ± 1.27 ** |
| PEP-M | 1.25 ± 0.33 ** | 5.00 ± 1.02** | 0.55 ± 0.15 ** | 1.38 ± 0.45 ** | 2.92 ± 1.35 ** |
| PEP-H | 1.24 ± 0.49 ** | 5.35 ± 1.07 ** | 0.53 ± 0.33 ** | 1.42 ± 0.40 ** | 3.09 ± 1.47 ** |
N: the normal group; NC: the negative control group; PC: the positive control group (Soybean, 0.6 g·kg−1 body weight); PE: the PE powder group (1.35 g·kg−1 body weight); PEP-L: the PEP low-dosage group (0.2 g·kg−1 body weight); the PEP-M: PEP middle-dosage group (0.4 g·kg−1 body weight); PEP-H: the PEP high-dosage group (0.8 g·kg−1 body weight). ## p < 0.01: compared with the normal group (N); * p < 0.05 and ** p < 0.01: compared with the negative control group (NC)
Effect of PEP on liver index and lipid profiles (n = 10, mean ± standard deviation).
| Groups | Liver index (%) | TC (mmol·gprot−1) | TG (mmol·gprot−1) |
|---|---|---|---|
| N | 3.63 ± 0.38 | 0.078 ± 0.004 | 0.051 ± 0.006 |
| NC | 4.43 ± 0.20 ## | 0.152 ± 0.008 ## | 0.096 ± 0.007 ## |
| PC | 3.66 ± 0.26 ** | 0.101 ± 0.02 ** | 0.060 ± 0.009 ** |
| PE | 3.75 ± 0.35 ** | 0.119 ± 0.014 ** | 0.066 ± 0.006 * |
| PEP-L | 4.07 ± 0.35 * | 0.109 ± 0.012 ** | 0.070 ± 0.005 |
| PEP-M | 3.70 ± 0.43 ** | 0.108 ± 0.013 ** | 0.061 ± 0.005 ** |
| PEP-H | 3.65 ± 0.50 ** | 0.120 ± 0.015 ** | 0.074 ± 0.009 |
##p < 0.01: compared with the normal group (N); * p < 0.05 and ** p < 0.01: compared with the negative control group (NC).
Effect of PEP on Aspartate Aminotransferase (AST) and Alanine Transaminase (ALT) in the serum and liver (n = 10, mean ± standard deviation).
| Group | Serum AST (U·L−1) | Serum ALT (U·L−1) | Liver AST (U·gprot−1) | Liver ALT (U·gprot−1) |
|---|---|---|---|---|
| N | 13.98 ± 0.80 | 4.27 ± 0.73 | 3.16 ± 1.37 | 5.08 ± 0.39 |
| NC | 28.68 ± 1.99 ## | 14.55 ± 1.51 ## | 12.15 ± 1.46 ## | 24.50 ± 1.35 ## |
| PC | 17.08 ± 1.96 ** | 9.71 ± 0.98 ** | 5.36 ± 0.91 ** | 8.92 ± 0.92 ** |
| PE | 20.67 ± 2.03 ** | 8.76 ± 0.94 ** | 6.84 ± 0.85 ** | 15.93 ± 1.23 ** |
| PEP-L | 23.32 ± 2.00 ** | 8.34 ± 1.02 ** | 6.25 ± 0.94 ** | 16.84 ± 1.01 ** |
| PEP-M | 22.66 ± 2.66 ** | 8.08 ± 0.76 ** | 5.10 ± 0.88 ** | 14.15 ± 1.46 ** |
| PEP-H | 20.19 ± 2.10 ** | 7.86 ± 0.92 ** | 7.00 ± 0.97 ** | 15.62 ± 1.07 ** |
##p < 0.01: compared with the normal group (N); ** p < 0.01: compared with the negative control group (NC).
Effect of PEP on superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activities and malondialdehyde (MDA) levels (n = 10, mean ± standard deviation).
| Group | Serum SOD (U·mL−1) | Serum | Serum MDA (nmol·mL−1) | Liver | Liver | Liver |
|---|---|---|---|---|---|---|
| N | 51.95 ± 8.14 | 2798.36 ± 186.85 | 10.37 ± 0.94 | 28.35 ± 4.91 | 371.92 ± 104.69 | 2.65 ± 0.35 |
| NC | 41.77 ± 7.20 ## | 2317.42 ± 330.65 ## | 13.72 ± 1.87## | 19.31 ± 3.78 ## | 268.11 ± 35.81 # | 3.47 ± 0.58 ## |
| PC | 50.14 ± 6.28 * | 2691.38 ± 119.74 ** | 10.96 ± 0.75** | 24.57 ± 4.05 ** | 347.23 ± 84.93 * | 2.90 ± 0.61 * |
| PE | 49.55 ± 5.54 * | 2607.26 ± 209.84 * | 11.29 ± 1.95 * | 24.20 ± 4.15 * | 352.80 ± 99.33 * | 2.91 ± 0.51 * |
| PEP-L | 46.03 ± 5.99 | 2673.23 ± 348.06 * | 11.53 ± 1.49 * | 22.93 ± 4.49 | 345.59 ± 92.85 * | 2.92 ± 0.64 |
| PEP-M | 51.02 ± 8.09 * | 2655.42 ± 381.07 * | 10.37 ± 0.97 ** | 24.50 ± 4.39 * | 349.73 ± 111.13 * | 2.89 ± 0.61 * |
| PEP-H | 50.56 ± 6.50 * | 2594.17 ± 348.20 | 10.57 ± 0.92 ** | 23.97 ± 3.49 * | 339.52 ± 129.96 | 2.95 ± 0.73 |
##p < 0.01: compared with the normal group (N); * p < 0.05 and ** p < 0.01: compared with the negative control group (NC)
Figure 4Changes in morphology and histopathology of liver. (a) Effect of PEP on liver morphologies in different groups, (b) Effect of PEP on histological structure of livers in different groups. Haematoxylin and eosin staining, Original mignification 400×.